Skip to content

Riociguat

Soluble Guanylate Cyclase Stimulator — CARDIOVASCULAR SYSTEM

Also known as: adempas, BAY 63-2521

OfpFDA approvedOrphan designationATC C02KX05

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Riociguat is an ofp drug in the Soluble Guanylate Cyclase Stimulator class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as Guanylate Cyclase Stimulators. DrugCentral lists 2 molecular targets, including GUCY1B3 and PDE7B. Recorded indications include Chronic thromboembolic pulmonary hypertension and Pulmonary arterial hypertension.

  • Approval status: ofp (first approved 2013 by the FDA).
  • Drug class: Soluble Guanylate Cyclase Stimulator.
  • Mechanism of action: Guanylate Cyclase Stimulators.
  • Molecular targets: GUCY1B3 and PDE7B (2 listed in DrugCentral).
  • Indications: Chronic thromboembolic pulmonary hypertension and Pulmonary arterial hypertension.
  • ATC code: C02KX05 (Antihypertensives for pulmonary arterial hypertension).
  • Molecular formula: C20H19FN8O2; molecular weight 422.42 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Chronic thromboembolic pulmonary hypertension
  • Pulmonary arterial hypertension

Contraindications (1)

  • Pregnancy, function

Mechanism & targets

Mechanism of action (MoA)Guanylate Cyclase Stimulators
Established pharmacologic classSoluble Guanylate Cyclase Stimulator

Molecular targets (2)

TargetGeneActionActivity
Guanylate cyclase soluble subunit beta-1GUCY1B3positive allosteric modulatorMEC 7.52
cAMP-specific 3',5'-cyclic phosphodiesterase 7BPDE7BunknownIC50 5.54

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2013-10-08FDA—BAYER HLTHCAREYes

ATC classification

ATC codeTherapeutic hierarchy
C02KX05CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › OTHER ANTIHYPERTENSIVES › Antihypertensives for pulmonary arterial hypertension

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Death2839.6
Hospitalisation2683.5
Dyspnoea1919.3
Fluid retention1758.7
Hypotension1542.2
Dyspnoea exertional1458.5
Pain in jaw1189.9
Pulmonary arterial hypertension1172.9
Headache1090.7
Dizziness886.4
Pulmonary hypertension774.6
Right ventricular failure755.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Riociguat is on its molecule page.

Molecular formulaC20H19FN8O2
Molecular weight422.42 g/mol
CAS number625115-55-1
InChIKeyWXXSNCNJFUAIDG-UHFFFAOYSA-N
PubChem CID11304743
COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=NC=CC=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Riociguat used for?

DrugCentral lists the following indications for Riociguat: Chronic thromboembolic pulmonary hypertension and Pulmonary arterial hypertension.

How does Riociguat work?

Riociguat is classified as Guanylate Cyclase Stimulators; its molecular targets in DrugCentral include GUCY1B3 (positive allosteric modulator) and PDE7B.

When was Riociguat first approved?

Riociguat was first approved by the FDA in 2013.

What drug class does Riociguat belong to?

Riociguat is in the Soluble Guanylate Cyclase Stimulator class.

What is the chemical formula of Riociguat?

Riociguat has the molecular formula C20H19FN8O2 and a molecular weight of 422.42 g/mol.

Browse: all drugs starting with R · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2013-10-08
AgencyFDA
Targets2
Indications2
FormulaC20H19FN8O2
DrugCentral ID4807
Interactive profile